Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) EPS (Weighted Average and Diluted) (2021 - 2023)

Cullinan Therapeutics has reported EPS (Weighted Average and Diluted) over the past 3 years, most recently at -$0.06 for Q4 2023.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.06 for Q4 2023, up 89.66% from a year ago — trailing twelve months through Dec 2023 was -$3.21 (down 234.87% YoY), and the annual figure for FY2025 was -$33.57, down 20.84%.
  • EPS (Weighted Average and Diluted) for Q4 2023 was -$0.06 at Cullinan Therapeutics, up from -$0.91 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for CGEM hit a ceiling of $3.77 in Q2 2022 and a floor of -$1.42 in Q1 2023.
  • Median EPS (Weighted Average and Diluted) over the past 3 years was -$0.54 (2022), compared with a mean of -$0.21.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 1147.22% in 2022 and later crashed 425.93% in 2023.
  • Cullinan Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.76 in 2021, then grew by 23.68% to -$0.58 in 2022, then surged by 89.66% to -$0.06 in 2023.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.06 (Q4 2023), -$0.91 (Q3 2023), and -$0.82 (Q2 2023) per Business Quant data.